ClinicalTrials.gg
CompletedNCT05507216Updated Sep 10, 2026Results posted

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

A Phase 3 interventional study of ABX464 and Placebo in Ulcerative Colitis, sponsored by Abivax S.A.. Completed at 262 sites in 27 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Abivax S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
636
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 123 studies in Colitis, Ulcerative with a site in Japan — 23 open to participants now, 48 under way, 25 of them phase 3. Colitis, Ulcerative · Japan.

Enrollment
27th of 110
636 · median 206
Started
2023
with 12 others
Phase 3
56 of 123
9 open now
Registered
78th of 123
by date

Among the 123 studies in Colitis, Ulcerative with a site in Japan, this one is the 27th largest by enrollment of the 110 interventional ones that give a count, is one of 13 that started in 2023, is one of 56 in phase 3, and was the 78th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

23 of the 123 studies in Colitis, Ulcerative with a site in Japan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Colitis, Ulcerative with a site in Japan, or all of them as a file.
02

Study summary

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority. If these approvals have not been granted, only subjects ≥ 18 years old will be enrolled. To be eligible, adolescent subjects must weigh ≥ 40 kg and meet the definition of Tanner Stage 5 at the screening visit.
  • Subjects must understand, sign and date the written voluntary form at the visit prior to any protocol-specific procedures. For under-aged subjects, national requirements regarding consent should also be met.
  • Documented diagnosis of UC confirmed by endoscopy and histology. Should endoscopy/histology results not be available at screening, results from endoscopies and taken at screening may be used.
  • Active disease defined by modified Mayo score (MMS) ≥ 5 with rectal bleeding subscore (RBS) ≥ 1 and endoscopy subscore (MES) of 2 or 3 (confirmed by central reader).
  • Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: , , biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted).
  • Women of (WOCBP) subjects and male subjects with WOCBP partner must agree to comply with the requirements described in the protocol.
  • Subjects able and willing to comply with study visits and procedures as per protocol.
  • Subjects should be affiliated to a health insurance policy whenever required by a participating country or state.

Exclusion criteria

Exclusion Criteria:

  • Subjects with UC limited to an isolated proctitis (≤ 15cm from anal verge) determined by endoscopy central reading.
  • Subjects with primary sclerosing cholangitis or hepatitis.
  • Subjects who have failed on 5-ASA or sulfasalazine therapy only.
  • Subjects with CD or presence or history of fistula, indeterminate colitis, infectious/ischemic colitis or microscopic colitis (lymphocytic and collagenous colitis).
  • History or current evidence of toxic megacolon, fulminant colitis, bowel perforation.
  • History of colonic cancer or colonic low grade or high grade dysplasia adenomatous polyps, and/or at the screening endoscopy, evidence of colonic cancer or evidence of low grade or high grade dysplasia adenomatous polyps (fully removed or not).
  • Recent or planned bowel surgery or history of proctocolectomy or partial colectomy or current stoma.
  • Subjects on antidiarrheals including those working on motility (e.g., loperamide, diphenoxylate with atropine, etc.).
  • Subjects on probiotics (e.g., Culturelle® [Lactobacillus GG, i-Health, Inc.], Saccharomyces boulardii).
  • Subjects who do not meet the requirements prior to the screening endoscopy.
  • Subjects with the following hematological and biochemical laboratory parameters obtained during the screening period:

    • ≤ 8.0 g dL-1
    • \< 750 mm-3
    • \< 100,000 mm-3
    • \< 60 mL.min-1 (Cockroft-Gault formula)
    • Total serum > 1.5 x
    • Alkaline phosphatase, (AST) and alanine aminotransferase (ALT) > 2 x ULN
  • Subjects with the following conditions (infection):

    • Subjects with chronic or recurrent grade 3 or grade 4 infection within the last 2 months prior to screening or a history of opportunistic infection while not on therapy.
    • Herpes zoster reactivation within the last 2 months prior to screening.
    • Subjects with active infection at screening or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 1 month of screening or during screening. Fungal infection of nail beds is allowed.
    • Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridium difficile toxin at screening. If C. difficile is positive, subject may be treated and retested ≥ 2 weeks after completing treatment.
    • Subjects with infection.
    • Subjects having acute or chronic infection at screening (positive for hepatitis B surface antigen [HbsAg], or negative for HbsAg and positive for anti-hepatitis B core antibody in conjunction with detectable HBV DNA, or detectable HBV DNA).
    • Subjects having acute or chronic infection at screening as defined by positive for hepatitis C antibody (subjects successfully treated and without recurrence ≥ 1 year with no detectable HCV RNA [assessed centrally] are eligible).
    • Active tuberculosis (TB) or untreated latent TB are ruled out. For subjects with positive or intermediate QuantiFERON test see the current study protocol.
  • Subjects with an uncontrolled ischemic heart disease and/or a history of congestive heart failure with (NYHA) class 3 or 4 symptoms.
  • Subjects with a family or personal history of congenital or acquired long syndrome, or subjects with a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval [Fridericia or Bazett correction] >450 milliseconds for male and > 460 milliseconds for female).
  • Subjects with a history of torsade de pointe (TdP).
  • Acute or chronic of pulmonary, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable central nervous system pathology such as seizure disorder, or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history (note: treated autoimmune hypothyroidy and autoimmune diabetes are allowed).
  • Serious illness requiring hospitalization within 4 weeks prior to screening (except UC flare).
  • Subjects previously treated with ABX464.
  • Subjects with a known to the active substance or to any of the .
  • subject who is pregnant or breast-feeding at screening, or intends to become pregnant during the study, or male subject with WOCBP partner who intends to be pregnant during the study.
  • Illicit drug or alcohol abuse or dependence.
  • Subjects who received within 3 months prior to screening and/or who's planning to receive such a vaccine during the study duration.
  • Use of any or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer, and during the study.
  • Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  • Any condition, which in the opinion of the investigator, could compromise the subject's safety or adherence to the study protocol.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
636 participants (actual)

Study arms

  • Experimental
    ABX464 50mg

    Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks

    Drug: ABX464

  • Experimental
    ABX464 25mg

    Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks

    Drug: ABX464

  • Placebo comparator
    Placebo

    Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks

    Drug: Placebo

Interventions

  • DrugABX464

    Administered once daily in the morning with food

    Also known as: Obefazimod

  • DrugPlacebo

    Administered once daily in the morning with food

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8

    To compare the efficacy of ABX464 versus placebo on clinical remission. Clinical remission is defined as stool frequency subscore (SFS) = 0 or 1 and rectal bleeding subscore (RBS) = 0, and Mayo Endoscopic Score (MES) = 0 or 1 (MES of 1 modified to exclude friability).

    Time frame: 8 weeks

Secondary outcomes

  1. Proportion of Subjects Who Achieve Endoscopic Improvement at Week 8

    To compare the efficacy of ABX464 versus placebo on endoscopic improvement. Endoscopic improvement is defined as Mayo Endoscopic Score (MES) = 0 or 1 (MES of 1 modified to exclude friability).

    Time frame: 8 weeks

  2. Proportion of Subjects Who Achieve Clinical Response Per MMS at Week 8

    To compare the efficacy of ABX464 versus placebo on clinical response as per MMS. MMS is the Modified Mayo Score. Modified Mayo score is a composite measure of ulcerative disease activity consisting of three components: stool frequency, rectal bleeding and endoscopic subscores. Each component is scored from 0 (normal or inactive disease) to 3 (severe activity). The total range score ranges from 0 to 9, with higher scores indicating more severe disease activity. Clinical Response is defined as a reduction from baseline in MMS ≥ 2 points and a relative reduction from baseline in MMS ≥ 30%, and a reduction from baseline in Rectal Bleeding Score (RBS) ≥ 1 point and/or RBS = 0 or 1.

    Time frame: 8 weeks

  3. Proportion of Subjects With HEMI Per Geboes at Week 8

    To compare the efficacy of ABX464 versus placebo on histologic-endoscopic mucosal improvement (HEMI). HEMI is defined as endoscopic improvement associated with histologic improvement per Geboes score.

    Time frame: 8 weeks

07

Results

Posted Sep 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneABX464 50mgABX464 25mgPlacebo
Started318159159
Completed291142145
Not completed271714
Withdrew: Adverse event1388
Withdrew: Lack of efficacy221
Withdrew: Lost to follow-up300
Withdrew: Protocol violation012
Withdrew: Withdrawal by subject963

Outcome measures

PrimaryProportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8

To compare the efficacy of ABX464 versus placebo on clinical remission. Clinical remission is defined as stool frequency subscore (SFS) = 0 or 1 and rectal bleeding subscore (RBS) = 0, and Mayo Endoscopic Score (MES) = 0 or 1 (MES of 1 modified to exclude friability).

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8
ParticipantsABX464 50mgABX464 25mgPlacebo
Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8631810
SecondaryProportion of Subjects Who Achieve Endoscopic Improvement at Week 8

To compare the efficacy of ABX464 versus placebo on endoscopic improvement. Endoscopic improvement is defined as Mayo Endoscopic Score (MES) = 0 or 1 (MES of 1 modified to exclude friability).

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieve Endoscopic Improvement at Week 8
ParticipantsABX464 50mgABX464 25mgPlacebo
Proportion of Subjects Who Achieve Endoscopic Improvement at Week 81133516
SecondaryProportion of Subjects Who Achieve Clinical Response Per MMS at Week 8

To compare the efficacy of ABX464 versus placebo on clinical response as per MMS. MMS is the Modified Mayo Score. Modified Mayo score is a composite measure of ulcerative disease activity consisting of three components: stool frequency, rectal bleeding and endoscopic subscores. Each component is scored from 0 (normal or inactive disease) to 3 (severe activity). The total range score ranges from 0 to 9, with higher scores indicating more severe disease activity. Clinical Response is defined as a reduction from baseline in MMS ≥ 2 points and a relative reduction from baseline in MMS ≥ 30%, and a reduction from baseline in Rectal Bleeding Score (RBS) ≥ 1 point and/or RBS = 0 or 1.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieve Clinical Response Per MMS at Week 8
ParticipantsABX464 50mgABX464 25mgPlacebo
Proportion of Subjects Who Achieve Clinical Response Per MMS at Week 82018553
SecondaryProportion of Subjects With HEMI Per Geboes at Week 8

To compare the efficacy of ABX464 versus placebo on histologic-endoscopic mucosal improvement (HEMI). HEMI is defined as endoscopic improvement associated with histologic improvement per Geboes score.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With HEMI Per Geboes at Week 8
ParticipantsABX464 50mgABX464 25mgPlacebo
Proportion of Subjects With HEMI Per Geboes at Week 8762112

Adverse events

Collected over Up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABX464 50mg0/318 (0%)6/318 (1.9%)115/318 (36.2%)
ABX464 25mg0/159 (0%)6/159 (3.8%)40/159 (25.2%)
Placebo0/159 (0%)7/159 (4.4%)32/159 (20.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventABX464 50mgABX464 25mgPlacebo
Colitis UlcerativeGastrointestinal disorders2/3182/1593/159
Blood Loss AnaemiaBlood and lymphatic system disorders0/3180/1591/159
Acute Coronary SyndromeCardiac disorders0/3180/1591/159
UveitisEye disorders0/3181/1590/159
Pancreatitis AcuteGastrointestinal disorders0/3181/1591/159
PyrexiaGeneral disorders0/3180/1591/159
Lipase increasedInvestigations0/3181/1590/159
PleurisyRespiratory, thoracic and mediastinal disorders0/3181/1590/159
VasculitisVascular disorders0/3180/1591/159
AnaemiaBlood and lymphatic system disorders1/3180/1590/159
Most frequent other events
Most frequent other events
EventABX464 50mgABX464 25mgPlacebo
HeadacheNervous system disorders82/31823/1599/159
NauseaGastrointestinal disorders29/31811/1593/159
AnaemiaBlood and lymphatic system disorders12/3186/15911/159
N-terminal prohormone brain natriuretic peptide increasedInvestigations7/3183/15911/159
Lipase increasedInvestigations19/3182/1594/159

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ABX464 50mgABX464 25mgPlaceboTotal
<=18 years2013
Between 18 and 65 years297153142592
>=65 years1961641
Age, Continuous
Age, Continuous(years)ABX464 50mgABX464 25mgPlaceboTotal
Mean41.4 ± 13.6441.3 ± 12.8341.6 ± 14.6841.4 ± 13.69
Sex: Female, Male
Sex: Female, Male(Participants)ABX464 50mgABX464 25mgPlaceboTotal
Female1386058256
Male18099101380
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABX464 50mgABX464 25mgPlaceboTotal
American Indian or Alaska Native1102
Asian662939134
Native Hawaiian or Other Pacific Islander0000
Black or African American63413
White231116108455
More than one race0011
Unknown or Not Reported1410731
Baseline weight
Baseline weight(kg)ABX464 50mgABX464 25mgPlaceboTotal
Mean71.75 ± 17.10173.37 ± 16.05073.91 ± 17.38772.69 ± 16.919
Duration of ulcerative colitis
Duration of ulcerative colitis(years)ABX464 50mgABX464 25mgPlaceboTotal
Mean7.74 ± 7.1937.92 ± 6.7697.75 ± 6.5037.79 ± 6.911
Number of participants with at least one prior AT-IR
Number of participants with at least one prior AT-IR(Participants)ABX464 50mgABX464 25mgPlaceboTotal
Count of participants1597679314
Number of participants with inadequate response to JAK inhibitors among participants with AT-IR
Number of participants with inadequate response to JAK inhibitors among participants with AT-IR(Participants)ABX464 50mgABX464 25mgPlaceboTotal
Count of participants33192072

3 further baseline measures are reported on the registry.

08

Study locations

262 sites
  • University of Alabama -Birmingham
    Birmingham, Alabama 35205, United States
  • Research Solutions of Arizona, PC
    Litchfield Park, Arizona 85340, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • National Institute of Clinical Research
    Bakersfield, California 93309, United States
  • Citrus Valley Gastroenterology
    Covina, California 91723, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Clinical Applications Laboratories
    San Diego, California 92103, United States
  • Santa Maria Gastroenterology Medical Group
    Santa Maria, California 93458, United States
  • Danbury Hospital
    Danbury, Connecticut 06810, United States
  • West Central Gastroenterology d/b/a Gastro Florida
    Clearwater, Florida 33762, United States
  • IHS Health
    Kissimmee, Florida 34741, United States
  • Research Associates of South Florida
    Miami, Florida 33134, United States
  • Sanchez Clinical Research, Inc
    Miami, Florida 33157, United States
  • Wellness Clinical Research
    Miami Lakes, Florida 33016, United States
  • Sarkis Clinical Trials - Parent
    Ocala, Florida 34474, United States
  • AdventHealth Medical Group
    Orlando, Florida 32804, United States
  • Arnold Palmer Hospital For Children
    Orlando, Florida 32806, United States
  • Omega Research Orlando, LLC
    Orlando, Florida 32808, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • GCP Clinical Research, LLC
    Tampa, Florida 33609, United States
  • University of South Florida - PARENT
    Tampa, Florida 33612, United States
  • The University of Iowa
    Iowa City, Iowa 52242, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Tandem Clinical Research, LLC
    Marrero, Louisiana 70072, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • BVL Clinical Research
    Liberty, Missouri 64068, United States
  • Premier Health Research
    Sparta, New Jersey 07871, United States
  • NY Scientific Corp.
    Brooklyn, New York 11235, United States
  • Mount Sinai
    New York, New York 10029, United States
  • Plains Clinical Research Center, LLC
    Fargo, North Dakota 58104, United States
  • Susquehanna Research Group, LLC
    Harrisburg, Pennsylvania 17110, United States
  • Frontier Clinical Research, LLC
    Uniontown, Pennsylvania 15401, United States
  • Rapid City Medical Center, LLC
    Rapid City, South Dakota 57701, United States
  • Digestive Health Research, LC
    Hermitage, Tennessee 37076, United States
  • Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Gastroenterology Consultants of South Texas, PA
    Harlingen, Texas 78550, United States
  • Digestive System Healthcare
    Pasadena, Texas 77505, United States
  • LinQ Research, LLC
    Pearland, Texas 77584, United States
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75703, United States
  • Richmond VA Medical Center
    Richmond, Virginia 23249, United States
  • Gastroenterology Consultants and Endoscopy Center of Southwest Virginia
    Roanoke, Virginia 24014, United States
  • The Vancouver Clinic
    Vancouver, Washington 98664, United States
  • DIM Clinica Privada
    Ramos Mejía, Buenos Aires, Argentina
  • CEMIC
    Buenos Aires, Ciudad Autonoma Buenos Aires 1431, Argentina
  • Hospital Britanico de Buenos Aires
    Buenos Aires, Ciudad Autonoma Buenos Aires C1280AEB, Argentina
  • Centro de Investigaciones Clinicas Baigorria
    Rosario, Santa Fe Province, Argentina
  • Centro de Investigacion CICE
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Centro de Investigaciones Medicas Tucuman
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Gastroenterología Diagnóstica y Terapéutica (Gedyt)
    Ciudad Autonoma Buenos Aires, C1117ABK, Argentina
  • GZA Ziekenhuizen
    Antwerp, 2018, Belgium
  • AZ Maria Middelares
    Ghent, 9000, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • University Clinical Centre of the Republic of Srpska
    Banja Luka, Bosnia and Herzegovina
  • General Hospital Prim.dr.Abdulah Nakas
    Sarajevo, Bosnia and Herzegovina
  • University Clinical Center Tuzla
    Tuzla, Bosnia and Herzegovina
  • HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará
    Fortaleza, Ceará 60430-370, Brazil
  • Hospital Aliança
    Salvador, Estado de Bahia 41920-180, Brazil
  • Cliagen - Clinica de Atencao em Gastroenterologia, Especialidades e Nutricao
    Salvador, Estado de Bahia, Brazil
  • L2IP - Instituto de Pesquisas Clínicas Ltda.
    Brasília, Federal District 70200-730, Brazil
  • CDC - Centro Digestivo de Curitiba
    Curitiba, Paraná 80430-160, Brazil
  • Instituto de Pesquisas em Saúde - Fundação Universidade de Caxias do Sul (IPS/FUCS)
    Caxias do Sul, Rio Grande do Sul 95070-560, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul, Brazil
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
    Botucatu, São Paulo 18618-686, Brazil
  • CECIP - Centro de Estudos Clínicos do Interior Paulista
    Jaú, São Paulo 17201-130, Brazil
  • Pesquisare Saúde
    Santo André, São Paulo 09080-110, Brazil
  • Praxis Pesquisa Medica
    Santo André, São Paulo 09090-970, Brazil
  • Irmandade da Santa Casa da Misericórdia de Santos
    Santos, São Paulo 11075-101, Brazil
  • Hepatogastro
    São Paulo, São Paulo 04543-011, Brazil
  • Hospital Sirio Libanes
    São Paulo, Brazil
  • Diagnostic Consultation Center CONVEX EOOD
    Sofia, 1680, Bulgaria
  • Acibadem City Clinic Mladost Eood
    Sofia, Bulgaria
  • MC Medica Plus
    Veliko Tarnovo, 5000, Bulgaria
  • (G.I.R.I.) GI Research Institute
    Vancouver, British Columbia V6Z 2K5, Canada
  • Gordon and Leslie Diamond Health Care Centre - Vancouver General Hospital
    Vancouver, British Columbia, Canada
  • Newfoundland and Labrador Health Services
    Winnipeg, Manitoba, Canada
  • London Health Sciences Centre (LHSC) - Victoria Hospital
    London, Canada
  • Poliklinika Borzan d.o.o
    Osijek, 31000, Croatia
  • University hospital centre Zagreb
    Zagreb, 10000, Croatia
  • Institut klinicke a experimentalni mediciny
    Prague, 14021, Czechia
  • CHU Nice - Hôpital de l'Archet 2
    Nice, Alpes Maritimes 06200, France
  • Hôpital Nord - CHU Marseille
    Marseille, Bouches-du-Rhône 13915, France
  • Hopital Rangueil
    Toulouse, Haute Garonne 31059, France
  • Institut des MICI
    Neuilly, Hauts De Seine 92200, France
  • CHU Rennes - Hôpital Pontchaillou
    Rennes, Ille Et Vilaine 35000, France
  • CHU de Grenoble - Hôpital Nord
    Grenoble, Isere 38043, France
  • Hospital de brabois
    Vandœuvre-lès-Nancy, Moselle 57070, France
  • CHU Lille - Hôpital Claude Huriez
    Lille, Nord 59037, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Rhone 69495, France
  • CHU Amiens - Hopital Sud
    Amiens, Somme 80054, France
  • Centre Hospitalier Départemental Les Oudairies
    La Roche-sur-Yon, Vendée 85925, France
  • Universitaetsklinikum Tuebingen
    Tübingen, Baden-Wurttemberg 72076, Germany
  • INLUGA im Haus der Gesundheit
    Ludwigshafen am Rhein, Rhineland-Palatinate 67067, Germany
  • Charité - Campus Charité Mitte
    Berlin, 10117, Germany
  • DRK Kliniken Berlin Westend
    Berlin, 14050, Germany
  • Krankenhaus Waldfriede e. V.
    Berlin, 14163, Germany

Showing the first 100 of 262 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Jun 2025, 28 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 28 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2022
First posted
Aug 18, 2022
StartActual
Jan 25, 2023
Primary completionActual
Jun 24, 2025
CompletionActual
Jul 15, 2025
Results first posted
Sep 10, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05507216
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Aug 18, 2022
Start date
Jan 25, 2023
Primary completion
Jun 24, 2025
Completion
Jul 15, 2025
Results posted
Sep 10, 2026
Last update
Sep 10, 2026

Study contacts

Severine Vermeire, MD, PhD
principal investigator · UZ Leuven, Belgium
Bruce Sands, MD, PhD
principal investigator · Mount Sinai Health System Digestive Disease Institute, New York USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion